The committee will discuss new drug application (NDA) 209500, lumateperone tosylate capsules for oral administration, submitted by Intra-Cellular Therapies, Inc., for the treatment of schizophrenia.
Back to All Events
Earlier Event: July 25
Arthritis Advisory Committee
Later Event: August 7
Antimicrobial Drugs Advisory Committee